Your browser doesn't support javascript.
loading
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Martínez González, Sonia; Hernández, Ana Isabel; Álvarez, Rosa María; Rodríguez, Antonio; Ramos-Lima, Francisco; Bischoff, James R; Albarrán, María Isabel; Cebriá, Antonio; Hernández-Encinas, Elena; García-Arocha, Jennifer; Cebrián, David; Blanco-Aparicio, Carmen; Pastor, Joaquín.
Afiliação
  • Martínez González S; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Hernández AI; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Álvarez RM; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Rodríguez A; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Ramos-Lima F; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Bischoff JR; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Albarrán MI; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Cebriá A; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Hernández-Encinas E; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • García-Arocha J; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Cebrián D; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Blanco-Aparicio C; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
  • Pastor J; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain. Electronic address: jpastor@cnio.es.
Bioorg Med Chem Lett ; 27(21): 4794-4799, 2017 11 01.
Article em En | MEDLINE | ID: mdl-29017786
A scaffold hopping strategy, including intellectual property availability assessment, was successfully applied for the discovery of novel PI3K inhibitors. Compounds were designed based on the chemical structure of the lead compound ETP-46321, a potent PI3K inhibitor, previously reported by our group. The new generated compounds showed good in vitro potency and selectivity, proved to inhibit potently the phosphorylation of AKTSer473 in cells and demonstrated to be orally bioavailable, thus becoming potential back-up candidates for ETP-46321.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Inibidores de Fosfoinositídeo-3 Quinase Tipo de estudo: Diagnostic_studies Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Inibidores de Fosfoinositídeo-3 Quinase Tipo de estudo: Diagnostic_studies Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article